Compare Berkshire Hathaway Inc Class B (BRK.B) vs Charles River Laboratories Intl. Inc (CRL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Berkshire Hathaway Inc Class B vs Charles River Laboratories Intl. Inc — how do they compare? Berkshire Hathaway Inc Class B trades at $489.96, while Charles River Laboratories Intl. Inc trades at $229.36 (market cap $11.14B). The key difference: Charles River Laboratories Intl. Inc is trading nearer its 52-week high, Berkshire Hathaway Inc Class B nearer its low. Which is the better fit depends on your goals.
| BRK.B | CRL | |
|---|---|---|
Sector | Financials | Health |
52-Week High | $513.70 | $233.60 |
52-Week Low | $459.10 | $145.57 |
Market Cap | — | $11.14B |
Enterprise Value | — | $14.00B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Berkshire Hathaway Class B shares (BRK.B) trade at $489.92, down 1.38% today, with a bullish technical signal driven by moving averages. Analyst consensus is positive with 57% buy ratings. The stock's fundamentals reflect Berkshire's diversified holdings and strong cash flow, though key valuation ratios are not provided in the current dataset.
The outlook remains favorable given institutional support and bullish technicals, but risks include market volatility and reliance on broad economic health. Upside potential hinges on continued operational performance across its subsidiaries and strategic capital allocation by management.
Charles River Laboratories (CRL) trades at $229.75, down 1.57% on the day, near its consensus price target of $229.80. The stock shows a bullish technical trend with strong moving average signals and support at $225. Fundamentally, CRL has beaten EPS estimates for three consecutive quarters but reported a net loss of $144.34 million in 2025, with negative profit margins. Recent news highlights collaborations in AI and NGS services, supporting growth prospects.
Outlook remains mixed: analyst consensus is strongly bullish with 72% buy ratings and a high target of $260, but profitability challenges and high P/E of 684.85 pose risks. Cash flow stability and strategic partnerships offer upside, while margin pressures and debt levels require monitoring for sustained recovery.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Berkshire Hathaway Inc Class B
Berkshire Hathaway is a holding company with diverse subsidiaries, primarily in insurance through Geico and its reinsurance groups. It reinvests profits into various industries, owning Burlington Northern Santa Fe (railroad), Berkshire Hathaway Energy, and major manufacturing, service, and retail businesses like Precision Castparts and Lubrizol. The company operates in a highly decentralized manner.
Read more on BRK.B →About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →
